BIOSET has entered into a collaboration with Bonn Biotech on the development of cell therapy drugs based on TCR-like antibodies

On September 8, 2022, BIOSAITU (Beijing) Pharmaceutical Technology Co.

Based on the fully independent intellectual property rights of the renmiceTM platform (RenMab? and RenLite? mice), BIOSAI further developed human HLA transgenic mice HLA/RenMab, and combined with the advantages of high-throughput antibody screening, established a TCR-like antibody technology platform, focusing on the discovery of antibodies against intracellular tumor-related antigens, breaking through the limitation that conventional antibodies can only recognize extracellular antigens

Relying on a number of world-class technology platforms independently developed and established, including the genome-wide T cell signal optimization technology platform (GSOP for T-cell), TCR high-throughput screening platform (HAP for TCR), personalized TCR-T cell production technology platform, T cell efficient delivery system platform (TDP), etc.

The two sides complement each other's strengths, and this strong alliance will promote the development of new cell therapy drugs and expand the potential of immunotherapy for the benefit of patients